Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

[1]  R. Heine,et al.  Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on β-cell disposition index in metformin treated patients with type 2 diabetes , 2011 .

[2]  R. Bergenstal,et al.  Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.

[3]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[4]  C. Clar,et al.  Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. , 2010, Health technology assessment.

[5]  J. Northrup,et al.  Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial , 2010, The Lancet.

[6]  M. Hanefeld,et al.  Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis , 2010, Diabetologia.

[7]  M. S. Lewis,et al.  Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. , 2010, The American journal of medicine.

[8]  Lewis J Smith,et al.  Lung function in young adults predicts airflow obstruction 20 years later. , 2010, The American journal of medicine.

[9]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[10]  P. Clauson,et al.  Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[11]  M. Hanefeld,et al.  Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis , 2010, Diabetologia.

[12]  B. Zinman,et al.  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) , 2010 .

[13]  A. D'Angelo,et al.  Exenatide versus glibenclamide in patients with diabetes. , 2010, Diabetes technology & therapeutics.

[14]  B. Hoogwerf,et al.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study , 2010, Cardiovascular diabetology.

[15]  M. S. Lewis,et al.  Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin , 2010, Diabetes Care.

[16]  S. Jones,et al.  Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study , 2009 .

[17]  R. Elashoff,et al.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? , 2009, Diabetologia.

[18]  K. Boye,et al.  Diabetes in Japan: a review of disease burden and approaches to treatment , 2009, Diabetes/metabolism research and reviews.

[19]  T. Vilsbøll.  The effects of glucagon‐like peptide‐1 on the beta cell , 2009, Diabetes, obesity & metabolism.

[20]  A. Farmer,et al.  Three-year efficacy of complex insulin regimens in type 2 diabetes. , 2009, The New England journal of medicine.

[21]  S. Norris,et al.  Exenatide efficacy and safety: a systematic review , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[22]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[23]  J. Rosenstock,et al.  Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes , 2009, Diabetes Care.

[24]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[25]  N. Marchionni,et al.  Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. , 2009, European journal of endocrinology.

[26]  R. Berria,et al.  Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.

[27]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[28]  A. Barnett.  New treatments in type 2 diabetes: a focus on the incretin‐based therapies , 2009, Clinical endocrinology.

[29]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[30]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[31]  R. Bergenstal,et al.  Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea , 2009, Current medical research and opinion.

[32]  T. Kadowaki,et al.  Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. , 2009, Endocrine journal.

[33]  R. Bergenstal,et al.  Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. , 2009, Current medical research and opinion.

[34]  V. Mohan,et al.  Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. , 2009, Diabetes research and clinical practice.

[35]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[36]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[37]  M. Hadders‐Algra,et al.  How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? , 2008, Archives of Disease in Childhood.

[38]  R. Busch,et al.  Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[39]  J. McGill,et al.  Fatty Acids and Insulin Modulate Myocardial Substrate Metabolism in Humans With Type 1 Diabetes , 2008, Diabetes.

[40]  D. Kendall,et al.  Metabolic Improvement Associated with Temporal Pattern of Weight Loss in Exenatide-Treated Patients With Type 2 Diabetes , 2008 .

[41]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[42]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[43]  Dennis D. Kim,et al.  The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes , 2007, Annals of Internal Medicine.

[44]  P. Home,et al.  Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267 , 2007, Diabetologia.

[45]  Dennis D. Kim,et al.  A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study , 2007, Diabetologia.

[46]  K. Yamazaki,et al.  The status of diabetes control and antidiabetic drug therapy in Japan--a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). , 2006, Diabetes research and clinical practice.

[47]  J. Leahy,et al.  Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .

[48]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[49]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[50]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[51]  D. Drucker,et al.  A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. , 2004, Diabetes.

[52]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[53]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[54]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[55]  Yazhou Li,et al.  Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. , 2003, The Journal of biological chemistry.

[56]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward , 2022 .

[57]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[58]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[59]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[60]  L. Ryysy,et al.  Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[61]  W. Manning,et al.  Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.

[62]  R. Holman,et al.  United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus , 1996, Annals of Internal Medicine.

[63]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.